NeuroSense Therapeutics Ltd. NRSN
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.44
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $6.2M | $5.7M | $7.3M | $5.6M | $1.4M | — | — | — |
| SG&A | $4.9M | $4.2M | $4.8M | $5.0M | $1.6M | — | — | — |
| Total operating expenses | — | — | — | $77.0K | $19.0K | — | — | — |
| Operating income | -$11.1M | -$9.9M | -$12.0M | -$10.6M | -$3.0M | -$2.9M | -$1.2M | — |
| Net income | -$11.1M | -$10.2M | -$10.1M | -$10.5M | -$3.2M | -$2.8M | -$1.2M | — |
| EPS, basic | -0.44 | -0.54 | -0.74 | -0.91 | -0.52 | — | — | — |
| EPS, diluted | -0.44 | -0.54 | -0.74 | -0.91 | -0.52 | — | — | — |
| Shares, diluted (wtd. avg.) | 25.5M | 18.6M | 13.6M | 11.5M | 6.2M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $166.0K | $3.4M | $2.6M | $3.5M | $11.1M | $699.0K | — | — |
| Total current assets | $778.0K | $4.4M | $2.9M | $7.4M | — | — | — | — |
| Property, plant and equipment | $58.0K | $66.0K | $85.0K | $77.0K | — | — | — | — |
| Total assets | $1.0M | $4.6M | $3.2M | $7.7M | $11.4M | $779.0K | — | — |
| Total current liabilities | $2.5M | $2.0M | $3.5M | $1.7M | — | — | — | — |
| Total liabilities | $2.6M | $2.0M | $4.9M | $1.9M | — | — | — | — |
| Retained earnings | -$47.8M | -$36.7M | -$26.1M | -$16.0M | — | — | — | — |
| Total equity | -$1.6M | $2.6M | -$1.8M | $5.8M | $10.8M | $659.0K | $918.0K | $109.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.7M | -$10.1M | -$8.4M | -$7.6M | -$1.5M | — | — | — |
| Depreciation and amortisation | $16.0K | $22.0K | $21.0K | $12.0K | $3.0K | — | — | — |
| Stock-based compensation | $2.1M | $557.0K | $1.5M | $1.7M | $1.2M | — | — | — |
| Capital expenditure | $8.0K | $3.0K | $29.0K | $70.0K | $17.0K | — | — | — |
| Investing cash flow | -$8.0K | $1.0K | $3.5M | -$3.6M | -$17.0K | — | — | — |
| Financing cash flow | $4.4M | $10.9M | $4.0M | $3.8M | $11.9M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-036970.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
- Investing cash flow
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$1.2M | -$2.8M | -$3.2M | -$10.5M | -$10.1M | -$10.2M | -$11.1M |
| Investing cash flow | — | — | — | -$17.0K | -$3.6M | $3.5M | $1.0K | -$8.0K |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |